MSD Ireland announces 330 new jobs

Monday, June 5, 2017

MSD, known as Merck in the U.S. and Canada, will create 330 new jobs and invest €280 million over the next three years at two of its Irish manufacturing sites—important links in MSD’s global network of manufacturing plants. MSD maintains headquarters for the company and manufacturing division in the U.S.

[Read More]

European Commission approves EUSA Pharma’s dinutuximab beta for neuroblastoma

Wednesday, May 10, 2017

EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has announced that the European Commission has approved Dinutuximab beta for the treatment of patients with high-risk neuroblastoma. Dinutuximab beta is the only anti-GD2 monoclonal antibody approved in the European Union (EU). EUSA Pharma will begin commercializing Dinutuximab beta across the EU immediately.

[Read More]

Stricter medical device regulations will improve patient outcomes

Thursday, May 4, 2017

Regulations for medical and diagnostic devices are changing in tune with advances in technology, new and innovative medical treatments, and the need for more effective diagnostic practices. Infiniti Research expects the market for medical devices to experience positive growth in the coming years as new rules and regulations eliminate counterfeit and dangerous products, increasing consumers’ trust and allowing established and reputable vendors to flourish.

[Read More]

AstraZeneca tops out new global R&D center and HQ in Cambridge, UK

Wednesday, April 26, 2017

AstraZeneca marks a key milestone in its successful move to Cambridge, U.K., with the “topping out” of its new, state-of-the-art, strategic R&D center and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community. Occupation of the site will begin in stages in 2018.

[Read More]

VolitionRX opens new R&D facility in Belgium

Monday, April 24, 2017

VolitionRx opened its new R&D facility. The new building will enable the company to increase capacity to carry out clinical trials and to expand its scientific team, thereby expediting the large number of trials underway. The new custom-designed facility comprises 9,000 square feet of office space and 10,000 square feet of high quality, purpose-built laboratory space. The facility is located in the Crealys Science Park, Isnes in the Wallonia region of Belgium, an area popular with other biotech and pharmaceutical companies.

[Read More]